Dermatologicals Market Size, Share, Growth, Trends, and Global Industry Analysis: By Disease Type (Acne, Dermatitis, Psoriasis, Skin Cancer, Rosacea, Alopecia, Others), By Type (Medical Dermatology, Surgical Dermatology, Paediatric Dermatology, Cosmetic Dermatology, Dermato-immunology, Others), By Route of Administration (Topical, Oral, Parenteral), By End User (Hospitals, Skin Clinics, Others) and Region Forecast 2020-2031

Dermatologicals market size was valued at US$ 24,542.1 million in 2024 and is projected to reach US$ 49,681.9 million by 2031, growing at a CAGR of 9.4% from 2025 to 2031. The market encompasses products, treatments, and therapies designed for the diagnosis, prevention, and management of skin, hair, and nail disorders. It includes prescription and over-the-counter (OTC) medications, dermatology devices, cosmeceuticals, and aesthetic procedures aimed at improving skin health and appearance.

The global market is experiencing significant growth, driven by the rising prevalence of skin conditions such as acne, psoriasis, eczema, and skin cancer, along with increasing consumer demand for advanced skincare solutions. Technological advancements, expanding medical aesthetics, and growing awareness of dermatological health further contribute to market expansion.

Facts & Figures

• Skin Disorders Prevalence: Acne affects approximately 85% of people aged 12–24 globally, making it one of the most common dermatological conditions.
• Psoriasis Cases: An estimated 125 million people worldwide suffer from psoriasis, accounting for around 2–3% of the global population.
• Skin Cancer Incidence: More than 1.5 million new cases of skin cancer are diagnosed annually worldwide, with melanoma being one of the deadliest forms.
• Aesthetic Dermatology Demand: Over 15 million minimally invasive cosmetic procedures (such as Botox and dermal fillers) are performed annually, highlighting the growing demand for cosmetic dermatology.

Key Developments

• In February 2025, Galderma launched its ready-to-use liquid neuromodulator, relabotulinumtoxinA (Relfydess), in Europe at IMCAS 2025. Approved in 14 European countries, it is the first neuromodulator to receive simultaneous approval for glabellar and canthal lines. Backed by Phase IIIb RELAX trial data, Relfydess showed rapid onset and sustained efficacy beyond six months.
• In October 2024, Kenvue, Inc., the world’s largest pure-play consumer health company by revenue, announced that its Neutrogena® brand is advancing dermatological beauty by forging multi-year partnerships with Dr. Dhaval Bhanusali, a renowned skincare innovator, and Dr. Muneeb Shah, the most followed dermatologist globally.
• In February 2024, Medicxi consolidated assets from six of its companies to establish Alys Pharmaceuticals, a new drugmaker dedicated to 14 immuno-dermatology programs. These programs target conditions such as atopic dermatitis, vitiligo, alopecia areata, and chronic spontaneous urticaria. Additionally, Alys Pharmaceuticals secured $100 million in funding from Medicxi.

Dermatologicals Market Segmentation

Based on the disease type

• Acne
• Dermatitis
• Psoriasis
• Skin Cancer
• Rosacea
• Alopecia
• Others

Acne remains the leading segment in the dermatological market, driven by its high global prevalence and increasing demand for effective treatment options. Factors such as hormonal imbalances, rising pollution levels, and changing dietary habits contribute to the growing incidence of acne, particularly among adolescents and young adults. The expanding skincare industry, fuelled by consumer awareness and social media influence, has led to a surge in demand for dermatologist-recommended treatments, including topical retinoids, benzoyl peroxide, and advanced laser therapies. Additionally, the rise of personalized skincare and AI-driven acne diagnosis tools is further driving market growth, making acne treatment a dominant segment in dermatology.

Based on the type

• Medical Dermatology
• Surgical Dermatology
• Paediatric Dermatology
• Cosmetic Dermatology
• Dermato-immunology
• Others

Medical dermatology holds the largest share in the dermatological market, driven by the increasing prevalence of chronic skin conditions such as acne, psoriasis, eczema, and rosacea. The rising demand for prescription-based treatments, including biologics, topical therapies, and oral medications, has significantly contributed to market expansion. Additionally, growing awareness about skin health and early diagnosis has led to higher patient visits to dermatologists for medical consultations. Advancements in dermatological research, along with the integration of tele dermatology and AI-based diagnostic tools, are further enhancing accessibility to treatments. The presence of strong pharmaceutical pipelines and continued R&D investments make medical dermatology the dominant segment.

Based on the route of administration

• Topical
• Oral
• Parenteral

Topical administration leads the dermatological market due to its convenience, effectiveness, and widespread use in treating various skin conditions such as acne, eczema, psoriasis, and dermatitis. The segment benefits from the availability of a broad range of formulations, including creams, gels, lotions, and ointments, which offer localized treatment with minimal systemic side effects. The increasing preference for over the counter (OTC) dermatological products, coupled with advancements in drug delivery systems such as nanotechnology and microencapsulation, is further boosting market growth. Additionally, the rising demand for cosmeceuticals and medicated skincare products has solidified topical administration as the leading segment in dermatology.

Based on the end user

• Hospitals
• Skin Clinics
• Others

Hospitals hold the largest share in the dermatological market due to their comprehensive healthcare facilities, access to advanced dermatology treatments, and availability of specialized medical professionals. Hospitals cater to a wide range of skin conditions, from common ailments like acne and eczema to severe cases such as skin cancer and autoimmune dermatological disorders. The presence of state-of-the-art diagnostic tools, biologic therapies, and surgical dermatology procedures further strengthens their market dominance. Additionally, hospitals often collaborate with pharmaceutical companies for clinical trials and research, ensuring the adoption of innovative dermatological treatments. The increasing number of dermatology departments in multispecialty hospitals further drives this segment’s growth.